↓ Skip to main content

Effects of young age at presentation on survival in breast cancer

Overview of attention for article published in BMC Cancer, July 2006
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
137 Dimensions

Readers on

mendeley
67 Mendeley
Title
Effects of young age at presentation on survival in breast cancer
Published in
BMC Cancer, July 2006
DOI 10.1186/1471-2407-6-194
Pubmed ID
Authors

Nagi S El Saghir, Muhieddine Seoud, Mazen K Khalil, Maya Charafeddine, Ziad K Salem, Fady B Geara, Ali I Shamseddine

Abstract

Young age remains a controversial issue as a prognostic factor in breast cancer. Debate includes patients from different parts of the world. Almost 50% of patients with breast cancer seen at the American University of Beirut Medical Center (AUBMC) are below age 50. We reviewed 1320 patients seen at AUBMC between 1990 and 2001. We divided them in three age groups: Below 35, 35-50, and above 50. Data and survival were analyzed using Chi-square, Cox regression analysis, and Kaplan Meier. Mean age at presentation was 50.8 years. 107 patients were below age 35, 526 between 35-50 and 687 patients above age 50. Disease stages were as follows: stage I: 14.4%, stage II: 59.9%, stage III: 20% and stage IV: 5.7%. Hormone receptors were positive in 71.8% of patients below 35, in 67.6% of patients 35-50 and in 78.3% of patients above 50. Grade of tumor was higher as age at presentation was lower. More young patients received anthracycline-based adjuvant chemotherapy. Of hormone receptor-positive patients, 83.8% of those below age 35 years, 87.76% of those aged 35-50 years, and 91.2% of those aged above 50 years received adjuvant tamoxifen. The mean follow up time was 3.7 +/- 2.9 years. Time to death was the only variable analyzed for survival analysis. Excluding stage IV patients, tumor size, lymph node, tumor grade and negative hormone receptors were inversely proportional to survival. Higher percentage of young patients at presentation developed metastasis (32.4% of patients below 35, as compared to 22.9% of patients 35-50 and 22.8% of patients above 50) and had a worse survival. Young age had a negative impact on survival of patients with positive axillary lymph nodes, and survival of patients with positive hormonal receptors, but not on survival of patients with negative lymph nodes, or patients with negative hormonal receptors. Young age at presentation conferred a worse prognosis in spite of a higher than expected positive hormone receptor status, more anthracycline-based adjuvant chemotherapy and equivalent adjuvant tamoxifen hormonal therapy in younger patients. This negative impact on survival was seen in patients with positive lymph nodes and those with positive hormonal receptors.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Brazil 1 1%
Unknown 65 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 21%
Other 9 13%
Student > Master 8 12%
Student > Ph. D. Student 7 10%
Student > Doctoral Student 5 7%
Other 16 24%
Unknown 8 12%
Readers by discipline Count As %
Medicine and Dentistry 32 48%
Agricultural and Biological Sciences 7 10%
Biochemistry, Genetics and Molecular Biology 4 6%
Nursing and Health Professions 3 4%
Unspecified 2 3%
Other 10 15%
Unknown 9 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2016.
All research outputs
#4,271,388
of 8,084,529 outputs
Outputs from BMC Cancer
#1,541
of 3,445 outputs
Outputs of similar age
#148,245
of 272,626 outputs
Outputs of similar age from BMC Cancer
#51
of 132 outputs
Altmetric has tracked 8,084,529 research outputs across all sources so far. This one is in the 27th percentile – i.e., 27% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,445 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,626 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.